Previous 10 | Next 10 |
Summary Baillie Gifford’s 13F portfolio value decreased from ~$97.51B to ~$96.99B this quarter. They increased Shopify, Roblox, Zoom Video, and Twilio while reducing Albemarle Corporation and Li Auto ADR. The top three positions are Tesla Motors, Moderna, and MercadoLib...
NEW YORK, Oct. 18, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at...
NEW YORK, Oct. 17, 2022 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on December 15, 2022, to shareholders of record ...
Royalty Pharma ( NASDAQ: RPRX ) said it signed an agreement with Merck ( NYSE: MRK ) to co-fund the development of MK-8189, which is being evaluated in a phase 2b trial to treat schizophrenia. Under the agreement, Royalty Pharma will provide $50M upfront t...
NEW YORK, Oct. 12, 2022 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to co-fund the development of MK-8189, an investigational oral PDE10A inhibitor currently being ...
Summary Halvorsen's 13F portfolio value decreased from $24.74B to $21.86B this quarter. The number of positions increased from 56 to 82. Viking Global added McKesson, American International Group, and Intuit while decreasing T-Mobile US, General Electric, and Brookfield Asset Mana...
Summary Blueprint has a few recently approved therapies, and has recently sold royalties for over $1 billion. While this limits revenue potential now, the profits can be leveraged back into advancing the pipeline. Blueprint can now be assessed like a pre-commercial biotech wit...
Royalty Pharma has agreed to acquire a royalty interest in Trelegy treatment from Innoviva, Inc. and Theravance Biopharma, Inc. for $1.3 billion in an upfront cash payment. The company is expecting this deal to add a minimum of $200 million to the adjusted non-GAAP cash receipt of RPR...
On August 15, institutional investment managers with more than $100 million AUM had to disclose their positions at the end of Q2 2022. I curated a list of some high-profile hedge funds and looked into their holdings at the end of June 2022. June was a temporary bottom in the marke...
Berkshire Hathaway's 13F stock portfolio value decreased from ~$364B to ~$300B. Their largest three holdings are at ~60% of the entire portfolio. Berkshire Hathaway increased Occidental Petroleum, Ally Financial and Paramount Global while decreasing STORE Capital and General Motor...
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, July 24, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced the appointment of Molly Sawaya as Executive Vice President, Head of Human Capital. Molly joins Royalty Pharma from Hudson Bay Capital, where she was a Managing Director and Head of Colleague Experie...
2024-07-24 08:08:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
NEW YORK, July 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its second quarter 2024 financial results on Thursday, August 8, 2024 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 ...